Logo

Bruce Compton, Steffen Nock, John Flavin, Karen Eastham, David Blow, Max Perutz, Bill Summers

Aug 06, 2004
Premium

Bruce Compton has become vice president and general manager for the chromatography business unit of Eksigent Technologies, the company said this week. He joins Livermore, Calif.-based Eksigent from Thermo Electron, where he was vice president and general manager for chromatography products. Prior to that, he was director of research and development for the chemical division, and later vice president of advanced separation technology, of Waters. Compton received a PhD from McGill University in Canada and a BA in biological sciences from the University of Hawaii.

Steffen Nock, co-founder and former vice president of biochemistry of protein chip company Zyomyx, has resurfaced as president of Absalus, a therapeutic antibody company based in Mountain View, Calif. He is also a co-founder of QualityProteomics, previously ProMab, located in Mountain View as well.

John Flavin has been promoted to president of Advanced Life Sciences of Woodridge, Ill., where he was CFO, the company said this week. Prior to joining ALS, he was COO of MediChem Life Sciences, also of Woodridge. He also served as CEO of MediChem’s protein engineering and proteomics subsidiaries, Emerald BioStructures, ThermoGen, and AXAS. Flavin holds an MBA from Lewis University in Romeoville, Ill., and a BS in business administration from Marquette University in Milwaukee.

Karen Eastham has been appointed to the board of directors of Illumina, the company said this week. She is executive vice president, COO, and a member of the board of trustees of the Burnham Institute. Prior to that, she was senior vice president and CFO of Diversa. Eastham holds an MBA and a BS from Indiana University.

David Blow died last month at his home in Appledore, England, at the age of 72. Working with Nobel laureate Max Perutz and others at Cambridge University in the U.K., he helped to develop protein X-ray crystallography in the 1950s, which he used to study the enzyme chymotrypsin.

Bill Summers was appointed on Thursday as the Global Sales Director in Informatics at Thermo Electron. Summers will be responsible for all commercial aspects of the company’s worldwide informatics business.

 

Filed under

Proteomics & Protein Research
proteomics
Breaking News
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.